Guided intelligence brief

Sleep depth.

Sleep-supportive peptide use is largely anecdotal. Mechanism is plausible for the GH secretagogue class; rigorous polysomnography data is limited.

01Mechanisms

How this class moves the outcome.

01

Nocturnal GH pulse amplification

GHRH-analogues and ghrelin-mimetics amplify the natural overnight GH surge, which correlates with slow-wave sleep in healthy adults.

02

Direct delta-sleep induction

DSIP was identified by its ability to induce delta-band EEG activity in animal models; human evidence is older and limited.

03

Pineal / circadian modulation

Epitalon is hypothesised to act on pineal melatonin signalling, though direct mechanism in humans is not well characterised.

02Candidate compounds

Ranked by human-evidence strength.

  1. 01

    DSIP

    Delta Sleep-Inducing Peptide

    Endogenous nonapeptide associated with delta-wave sleep. Effects on sleep architecture are inconsistent in human trials.

    Nonapeptide (sleep modulator)~7 minHuman observational
    BHuman observational
    5.2EIS™ · Emerging
    Open full brief →
  2. 02

    Epitalon

    Epithalon

    Russian synthetic pineal-gland tetrapeptide. Marketed for longevity; evidence largely Russian/in-house.

    Pineal tetrapeptideShortPreclinical only
    CPreclinical only
    3.9EIS™ · Emerging
    Open full brief →
  3. 03

    Ipamorelin

    Selective GH secretagogue with minimal effect on cortisol or prolactin. Reported for sleep and recovery.

    Growth hormone secretagogue~2 hPreclinical only
    CPreclinical only
    3.9EIS™ · Emerging
    Open full brief →
  4. 04

    CJC-1295 (with DAC)

    DAC:GRF

    GHRH analogue with drug-affinity complex extending half-life to days. Sustained elevation of GH/IGF-1.

    GHRH analogue (long-acting)~6–8 daysPreclinical only
    CPreclinical only
    3.9EIS™ · Emerging
    Open full brief →
  5. 05

    Sermorelin

    GRF 1-29

    Synthetic GHRH(1-29) historically marketed as Geref. Common in US anti-aging compounding.

    GHRH analogue~10–20 minHuman RCT
    AHuman RCT evidence
    6.5EIS™ · Moderate
    Open full brief →
03Human evidence

What the human data actually shows.

Brief composition
Evidence composition5 entries
RCT 1 Obs 1 Pre 3

Each bar is the proportion of candidates on this brief at that evidence tier. RCT first, observational second, preclinical and anecdotal labeled and never inflated.

See full methodology →
Outcome matrix
Subjective sleep quality
Self-report dominant; placebo-sensitive.
Cgrade
5.0
Slow-wave sleep (polysomnography)
Plausible mechanism; small studies.
Cgrade
4.8
Sleep onset latency
Dgrade
3.0
Daytime alertness / next-day cognition
Dgrade
2.8
04Risks & limitations

Where this class can hurt you.

Top class-level risks
  • GH-axis modulation can affect insulin sensitivity over time.
  • Most peptides in this class are research-use-only; product identity is not verified.
  • Subjective sleep gains often reflect placebo effects unmeasured in informal use.
What we still don't know
  • Most reports rely on subjective sleep scoring rather than objective sleep architecture.
  • Pulsatile GH dynamics may not translate to a measurable next-day outcome for everyone.
05Comparison

Decide between candidates.

Put the top 4 candidates side by side.

Mechanism · half-life · routes · evidence tier · safety signals. A decision matrix, not a leaderboard.

06Consensus engine

Current scientific consensus.

4.2/ 10
Overall confidence
Emerging
Human evidence
Emerging
Risk profile
Moderate
Strongest supported
  • Mechanistic plausibility for GH secretagogues
Weak / unclear claims
  • Reliable next-day cognitive benefit
  • Equivalence to validated sleep hygiene
Major unknowns
  • Long-term metabolic impact
  • Dose response on objective sleep architecture
Editorial outlook

"An emerging category. Plausible mechanism, weak objective endpoints. Validated sleep hygiene still outperforms."

07Long-term outlook

Where this is heading.

An emerging category. Plausible mechanism, weak objective endpoints. Validated sleep hygiene still outperforms.

We re-grade this brief quarterly. Confidence and outcome grades shift as new RCTs publish, safety data accumulates, and replication efforts read out. Changes are logged publicly on the evidence changelog.

06Canonical, evidence-anchored

Matched protocol templates.

Matching templates…